Jelly Beans Group has signed a three-party agreement that gives it exclusive sales and marketing rights in Japan for South Korean femcare brand iHEAL. BIOLAB Corp. will manufacture and supply the products, AIDEN LAB JAPAN will handle import intermediation and domestic licensing, and Jelly Beans says it will sell through direct, wholesale and online channels. Full-scale sales are planned for the second half of the year ending January 2027.
| Feature | Details |
|---|---|
| Exclusive rights | Jelly Beans Group gets exclusive sales and marketing rights in Japan and acts as general distributor. |
| Manufacturing and supply | BIOLAB Corp. |
| Imports and licensing | AIDEN LAB JAPAN handles import intermediation, domestic licensing and official distribution management. |
| Planned sales channels | Direct, wholesale and online. |
| Launch timing | Full-scale sales planned for the second half of the year ending January 2027. |
That gives the company a concrete route into femcare using a customer network it says was built over roughly 50 years in women's footwear. The main filing describes iHEAL as a women's inner-care and femcare brand from South Korea, while the supplemental slides outline products ranging from probiotics to wash, mist and beauty items. But the Japan lineup is not fixed yet: the company says the final products, pricing, labeling and regulatory classification for Japan will be decided later.
Investors should also note what is missing. Jelly Beans did not disclose the contract value, duration, minimum order quantities or other detailed commercial terms. It also said any sales or profit contribution from the launch is not yet included in full-year guidance and remains under review. In other words, the deal is signed, but the economics for the current year are still being worked through.